Dyslipidemia

The first in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on basic considerations surrounding Lp(a) measurement.

A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.

Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.

Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.

New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

Verve Therapeutics announced plans to voluntary pause enrollment of the Heart-1 trial, citing an adverse event and consultation with DSMB, with plans to shift focus to VERVE-102 and Heart-2 trial.

This clinical quiz will test your knowledge on management of LDL-C special populations with nonstatin therapies based on the ACC's 2022 expert clinical decision pathway.

An analysis of the CLEAR Outcomes trial suggests bempedoic acid was well-tolerated in Hispanic/Latinx and non-Hispanic/Latinx individuals with statin intolerance.

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).

Adults with higher triglyceride levels exhibit a higher prevalence of chronic conditions and multi-organ disease.

This clinical quiz will test your knowledge on the use of non-statin therapies for LDL-C lowering based on the American College of Cardiology's 2022 Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.

Presence of nephritis in SLE patients is linked to higher cardiovascular risk factors and 3-fold increase in incidence of cardiovascular mortality.

A significant association between Lp(a) and adverse cardiovascular outcomes was altered by renal function in patients undergoing percutaneous coronary intervention.

Implementing a Food as Medicine program improved diet, physical activity, and reduced cardiovascular risk factors among participants.

The FDA's approval of the label expansion for bempedoic acid to include cardiovascular risk reduction is based on data from the CLEAR Outcomes trial.

Elevated Lp(a) may influence LDL-C levels and prevent LDL-C target achievement in patients at very high cardiovascular risk.

An analysis of 3 randomized clinical trials from the evinacumab program suggests the ANGPTL3 inhibitor was associated with reduced triglyceride-rich lipoprotein levels.

A recent comparison of changes in Lp(a) mass and molar concentrations found that each assay method was similarly predictive of MACE reductions with alirocumab.

An analysis of NHANES data suggests fewer than 3 in 10 patients with NAFLD received statin therapy, with only 50% with dyslipidemia receiving statins.

Silence Therapeutics' announcement of topline data from the ALPACAR-360 trial shows promising results for zerlasiran in reducing Lp(a) levels.

New data from the Family Heart Foundation highlights low access to PCSK9 inhibitors due to insurance rejections, despite guidelines recommending their use for high-risk patients.

Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.